---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-25-000106"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T16:57:42.859126+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M

## Summary
- Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
- FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.
- Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.
- Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.
- Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026.

## SEC filing metadata
- accession: 0001005286-25-000106
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/0001005286-25-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/lndc-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-25-000106
- JSON: https://secwatch.observer/filing/0001005286-25-000106.json
- Plain text: https://secwatch.observer/filing/0001005286-25-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.